Background
Introduction
Metabolic syndrome (MetS) is a syndrome described as a clustering of metabolic risk factors including abdominal obesity, elevated blood glucose and triglycerides, reduced HDL cholesterol and hypertension. It has been described as being associated with an increased risk of type 2 diabetes, myocardial infarction, stroke, heart failure and cardiovascular mortality. In western populations and in the developing world the burden of MetS has reached epidemic proportions and is fast becoming one of the greatest global public health concerns with a prevalence of 34% in the general population [1] .
Recent studies have highlighted the importance of the MetS and its components for the development and progression of heart failure [2, 3, 4, 5] . MetS increases the risk of myocardial infarction and chronic ischaemia, both of which predispose to heart failure with reduced ejection fraction (HFrEF). It can also lead to heart failure with preserved ejection fraction (HFpEF) via different pathophysiological pathways. It has been shown that the prevalence of left ventricular (LV) diastolic dysfunction is significantly higher in patients with MetS compared to those without (35% vs. 9%) [6, 7] . A large multicentre study which evaluated 6422 asymptomatic patients with LV dysfunction demonstrated the relevance of MetS as an independent predictor of diastolic dysfunction after adjustment for age, gender and myocardial hypertrophy. Furthermore, the degree of diastolic dysfunction was dependent on the number of individual MetS components [8] .
A diagnosis of HFrEF is usually made after the patient presents with an acute decompensation, often with pulmonary oedema, and frequently after a period of silent LV remodelling, neurohormonal activation and sub-clinical fluid retention. Echocardiographic screening programmes in at-risk subjects can detect pre-symptomatic cases at high risk of HFrEF. The situation for HFpEF is however, more complicated, as the diagnosis can be harder to make in the early course of the syndrome, with reduced exercise tolerance and occasional dyspnoea being ascribed to the effects of advancing age and common co-morbidities, such as obesity and lung disease.
Currently, little is known about the early development and early clinical diagnosis of HFpEF in patients with metabolic syndrome, and thus opportunities to intervene early in MetS to reduce both the prevalence of HFpEF and its subsequent clinical course are being lost. Given the high prevalence of diastolic dysfunction in this population, we hypothesized that a significant number of patients with MetS may already have unrecognized HFpEF. The purpose of the study was thus to investigate the possibility of detecting an early phase of HFpEF by means of exercise capacity evaluation and biomarker testing. Additionally, we sought to examine the potential association between markers of arterial stiffness an early HFpEF within a community identified MetS population.
Methods
The study was approved by the local Ethics Committee and written informed consent was obtained from each patient. The investigation conforms with the principles outlined in the Declaration of Helsinki (Br Med J 1964; ii:177).
Study populations a. Screening Programme Cohort with MetS:
We prospectively enrolled 148 patients with MetS (mean age 56. 
b. Clinical HFpEF Cohort with MetS:
We recruited 38 patients (mean age 61 ± 10.5 years, 16 (42.1%) males) who had both a past clinical diagnosis of HFpEF (clinically diagnosed heart failure with left ventricular ejection fraction >50%) and who also satisfied our criteria for MetS (as described below). These subjects were recruited from patients who had been referred to the cardiopulmonary exercise laboratory for evaluation of heart failure, or for the differential diagnosis of dyspnoea. Seventy-one percent of this cohort had a history of hospitalisations due to cardiovascular diseases (CVD).
Definitions and Testing Protocols: Definition of Metabolic Syndrome
We used the definition of 
Detection of early HFpEF
We defined early HFpEF as the presence of either an objective impairment of exercise tolerance (peak VO 2 ≤90% of its predicted value on valid symptom-limited cardiopulmonary exercise testing) or an objective biomarker suggestive of increased myocardial wall stress (BNP level 35 ng/l or higher). Based on these two criteria the screening MetS cohort was divided into two subgroups: those with and those without signs of early HFpEF.
Cardiopulmonary stress test
The cycle ergometer was set to a ramp mode for individually tailored incremental testing, each increment varied from 15 to 30 W per minute. The exercise protocol was designed to last approximately 8-12 minutes. Throughout the test, blood pressure and constant electrocardiographic monitoring was applied. Prior to the exercise test, spirometry was performed for each subject using a manually calibrated spirometer (SensorMedics, USA). Expired gases during the test were measured and analyzed using a "breath-by-breath" respiratory mass spectrometry system (Vmax ® Encore 229, SensorMedics, USA) that was automatically calibrated before each test. The anaerobic threshold and VAT were determined by the "V-slope" method (VCO 2 /VO 2 ratio) -the first curve inflection [9] 1986.-Excess CO2 is generated when lactate is increased during exercise because its [H'] is buffered primarily by HCO: (22 ml for each meq of lactic acid. Peak oxygen consumption (VO 2 peak) was considered to be achieved if VO 2 reached a plateau for at least 30 sec. in the presence of an increasing power output (W) [10] 19&Z.-This study was undertaken to determine which of four com-monly used ventilatory or gas exchange indices provides the most accurate and reliable detection of the anaerobic threshold (AT. If the subject was exhausted before the attainment of VO 2 peak, the VO 2 value was accepted as a reasonable maximum if the heart rate was >85% of the predicted maximum rate and a respiratory quotient (RQ) >1.00 was recorded.
BNP testing
The Abbott ARCHITECT immunoassay analyzer was used for the diagnosis of BNP concentration in plasma (units of measure -ng/l).
Echocardiographic diagnosis of LV Hypertrophy
Two-dimensional echocardiography was performed using ultrasonic system equipped with a According to recommendations for chamber quantification, LV hypertrophy was diagnosed when LV mass index made ≥95 g/m² in women and ≥115 g/m² in men and/or relative wall thickness ≥0,42 [11] . In our study 68.4% of the clinically diagnosed and 60.8% of the Screening Cohort patients had LV hypertrophy.
Definition of LV Diastolic Dysfunction
Assessment of LV diastolic function included trans-mitral pulsed wave Doppler with evaluation of peak velocities of early diastolic flow (E) and peak flow of atrial contraction (A), E/A ratio, as well as tissue Doppler imaging parameters with early (E') and late (A') diastolic mitral medial and lateral annular velocities. The left atrial volume (LAV) was measured by the biplane area-length method and indexed to the BSA.
Diastolic dysfunction was defined according to the 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [12] . Impaired relaxation was described as E/A <1.0 and E/e' mean <13. Participants were considered as having pseudo-normal or restrictive diastolic dysfunction if the E/e'mean ratio was ≥13. In case of E/A >1.0 and e' septal ≥8 cm/s and e' lateral ≥10 cm/s diastolic function was interpreted as normal.
Arterial Markers of Subclinical Atherosclerosis Arterial stiffness measurements
Parameters of arterial stiffness and wave reflection were assessed by applanation tonometry (SphygmoCor, AtCor Medical, version 8.0, Sydney, Australia) and Fukuda Vascular Screening system VaSera VS-1000 (Fukuda Denshi Co. Ltd., Tokyo, Japan). Using SphygmoCor system, radial, carotid and femoral pressure waveforms were recorded for 20 seconds each with single transducer synchronized with ECG R wave, after obtaining high quality waveform. Carotid femoral pulse wave velocity (cfPWV), which represents more selectively central arterial wall stiffness, was calculated automatically as the distance divided by time (meters per second). Aortic pressure waveform with calculation of heart-rate 75 bpm adjusted aortic augmentation index (AIx@ HR75) was automatically derived from radial pressure waveform using previously validated transfer function. VaSera VS-1000 system was used for the measurement of ankle-brachial index (ABI), which rates the presence of peripheral artery disease. ABI was calculated automatically from the pressure curves.
Common carotid artery wall assessment
Carotid intima-media thickness (IMT) is an anatomical measure which is used for the detection of subclinical atherosclerosis, from early to late stages. High-resolution echo-tracking technology (Art.Lab; Esaote Europe, Maastricht, The Netherlands) was used for the evaluation of carotid IMT, calculated in μm, and the non-dimensional index QCS of CCA.
The measurements were performed at 1 cm proximal to the carotid bifurcation along 4 cm arterial segment.
Assessment of endothelial function
Reactive hyperaemia index, which evaluates endothelial function in the microcirculation, was measured by peripheral arterial tonometry (PAT) (EndoPAT 2000 system; Itamar Medical, Caesarea, Israel) in fasting patients.
Statistical analysis
Statistical analysis was performed using SPSS Statistics version 24.0 (IBM Corp., Armonk, NY, USA). Descriptive parameters are presented as mean ± standard deviation or in percentages. Two-tailed t-tests and Pearson's chi-square tests were used to analyse the differences in means between groups which were considered to be statistically significant when p value < 0.05.
Results
Complete data were available for 148 screening subjects and 38 clinical HFpEF subjects. The characteristics of both groups are presented in Table 1 . The most frequent components of the metabolic profile in the Screening Cohort were: increased waist circumference (96.0%), elevated blood pressure (90.5%) and increased fasting serum glucose (70.3%), and in the Clinical HFpEF patients group: high blood pressure (86.8%), low HDLcholesterol level (84.2%) and increased fasting serum glucose (76.3%). The vast majority of all study patients presented with diastolic dysfunction, and up to 2/3 had LV hypertrophy. In 44 participants (29.7% of the screening cohort) an elevated BNP of ≥35 ng/l was found. 96 out of the 148 MetS subjects in the screening cohort (65%) demonstrated either a reduced exercise capacity and/or an elevated BNP consistent with the early signs of HFpEF ( Figure 1 ).
Markedly higher values of BNP, E/E', LAVI and VE/VCO 2 were observed in the clinical HFpEF group compared to the Screening Cohort with early HFpEF perhaps suggesting a later stage of HF with more abnormal diastolic dysfunction compared to the early HFpEF of the Screening Cohort. It could also be that a diagnosis of HFpEF may be more likely to be made if patients with the same symptoms and objective limitation demonstrate these changes on echocardiography. There was also a lower HDL-cholesterol and a higher VE/VCO 2 in the clinical HFpEF group that might suggest more advanced disease affecting the whole body as is described in the muscle syndrome of heart failure [13] . The analysis of arterial markers in the Screening Cohort revealed a statistically significant association of heart-rate 75 bpm adjusted aortic augmentation index (AIxHR75) with the detection of early HFpEF (p=0.016). There were no differences between mean systolic (p=0.416) and mean diastolic (p=0.440) blood pressure comparing those with and without early HFpEF. The data of all investigated markers of preclinical atherosclerosis are presented in Table 2 . More than 75% of the entire Screening Cohort had impared endothelial function, showing how common this abnormality is within the MetS population.
Discussion
The metabolic syndrome has been identified as one of the major factors in the development of HF. A Japanese clinical study has revealed that the prevalence of MetS in HF patients is more than double compared with the general population. This is true for both HFrEF and for the less well studied HFpEF population, with a significantly higher prevalence of HFpEF in the MetS group in comparison with non-MetS group in this study [14] . The Framingham Heart Study showed that after adjustment for known risk factors each increase of 1 point in BMI increased the risk of heart failure (not differentiating HFrEF from HFpEF) by 5 percent for men and 7 percent for women [15] .
To our knowledge, this is the first study that addresses the early detection of HFpEF in MetS patients using a combination of BNP and peak VO 2 . In our previous study of a large cohort of MetS patients [16] , we showed that the vast majority of subjects had diastolic dysfunction, and even more than half of them showed a pseudo-normal pattern, consistent with elevated LV filling pressures. Thus, we postulated that in the group of patients, who have a high risk of HF development, a very early phase of HFpEF is already present and presumably can be detected by functional and biomarker testing. Indeed, in our prospectively enrolled MetS population without established overt cardiovascular disease we found a sizeable subgroup (up to two thirds) of patients with impaired functional capacity, elevated neurohormonal activation and ultrasound evidence of elevated LV filling pressures. Assignment of an HF diagnosis to such patients is largely in accordance with more recently refined HFpEF definitions the recent ESC guidelines [12] ; with the components of the diagnosis including an increased BNP level, and objectively documented impaired exercise capacity. An advantage of our report is the consistent use of cardiopulmonary exercise testing in order to elicit an objective decrease of exercise tolerance, and by the use of respiratory gas analysis establish it is truly cardiac related limitation. Clinically it is noted that in many subjects with HFpEF a loss of functional capacity can be ascribed to unfitness or age, and the true limitation due to cardiac disease frequently not being adequately appreciated by the patients themselves.
Looking to the subjective self-evaluation of symptoms, it has been shown that the use of self-rated health (SRH), assessed through a single question [17] [18] , is limited for patients with asymptomatic left ventricular diastolic dysfunction, for the reason that such subjects understate their complaints. A Swedish study has shown that the majority of participants with asymptomatic left ventricular diastolic dysfunction rated their health status as good or very good, despite the high prevalence of comorbidities [19] . Therefore, there is a need for comprehensive diagnostic methods that would help to highlight the symptoms. Cardiopulmonary exercise testing is an established tool for the evaluation of the disease severity and prognosis in heart failure patients. Our study also suggests a clinically relevant value for its use in the early detection of reduced exercise tolerance in subjects enrolled in the screening and prevention program. Though only 11.5% of patients with the signs of early HFpEF had documented complaints of dyspnoea, the cardiopulmonary stress test revealed objectively impaired exercise tolerance in 83.3% of these patients.
The most recently published of the major guidelines for heart failure, the ESC HF guidelines suggest an elevated BNP level as a necessary component for the establishment of an HFpEF diagnosis. In parallel with the substantially increased BNP levels in clinically labelled advanced HFpEF patients, we were also able to show a modest but statistically significant elevation of BNP in the subgroup of MetS population with early HFpEF.
One can speculate that the group with undetected HFpEF could be differentiated even more precisely if there was no inverse impact of MetS on BNP -as has been previously demonstrated BNP values are significantly lowered in persons affected by MetS [20] .
Several hypotheses attempt to explain the inverse relationship between BNP levels and obesity. The renal theory states that BNP levels are depressed because of higher glomerular filtration rates which lead to more efficient molecular clearing [21] even in the absence of diabetes, contributes significantly to the development and progression of chronic kidney disease (CKD. The adipose tissue theory states that the reason for reduced BNP values in MetS is due to the effect of natriuretic peptide clearance receptor-C (NPR-C) changes [22] [23] . On the contrary, the Framingham Heart Study [24] and the Dallas Heart Study [25] questioned this theory showing that NT-proBNP values in obesity are also reduced even though it is not cleared by NPR-C. The Dallas Heart Study authors found that both BNP and NTproBNP values were more closely associated with lean mass than with BMI. Due to this finding they theorized that rather than the adipose tissue itself being the main factor causing lowered BNP values, a substance produced in the lean tissue could suppress either BNP synthesis or its release from cardiomyocytes.
Two MetS criteria, insulin resistance and lipid abnormalities, are considered as the main components that influence progression of the disease, whereas obesity and high blood pressure are linked to the outcomes in HF patients [5] . A recently presented new paradigm for HFpEF emphasizes the importance of obesity as one of the main comorbidities which induces a systemic inflammatory state that sequentially leads to diastolic LV dysfunction [26] .
Diastolic dysfunction as a leading mechanism in the formation of HFpEF was detected in most of the study patients. Only 3.4% of the screening cohort and 2.6% of clinical HFpEF patients had normal diastolic function. The most common grade of diastolic dysfunction in both prospective subgroups was impaired relaxation, whereas the clinical HFpEF group mostly presented with a pseudo-normal filling pattern.
Arterial markers of preclinical atherosclerosis are used for early prediction of cardiovascular risk and the impact of MetS on arterial elastic properties is intensely discussed [16, 27, 28] . Aortic pulse wave velocity, an index of aortic stiffness, has been shown to be an independent determinant of LV diastolic dysfunction. Moreover, significant correlations between aortic PWV, augmentation index and diastolic function parameters, such as the E/A ratio, E/E' ratio were demonstrated [16, 28] .
In the present study we found a markedly higher AIxHR75 in subjects with early HFpEF compared to those without. Our data support the concept that increased aortic stiffness plays a role in the development of LV diastolic dysfunction and subsequent HF. However, to the best of our knowledge, there are no data or analysis of the relation between markers of preclinical atherosclerosis and heart failure markers. Therefore, further investigation of any possible connection between alterations in arterial stiffness and their influence on LV diastolic dysfunction and HFpEF is needed in a bigger cohort of MetS subjects.
Kosmala et al. highlighted the value of early functional markers such as LV strain in the detection of asymptomatic LV impairment in subjects with type 2 diabetes, hypertension or obesity. The study showed that myocardial strain analysis increased the possibility to detect early LV dysfunction which in turn is associated with impaired exercise capacity Furthermore, subclinical myocardial systolic dysfunction characterized by impaired global longitudinal strain is strongly associated with a larger epicardial adipose tissue volume typical for MetS [30] . In addition this work my have implications for effective treatments in selected HFpEF patients if as suggested the metabolically abnormal syndrome we see and that also occurs in obese HFpEF may respond to particular targetted therapeutics strategies [31, 32] .
Limitations
The present study is limited because of its relatively small number of participants; more pronounced results could be expected in the association of HF signs with distinct metabolic components and arterial markers in a bigger cohort. An alternative HF biomarker not affected by obesity is warranted for studies in early HFpEF. The addition of habitual physical activity to the objective measurement of exercise capacity may strengthen the study results and predictive capacity.
Conclusions
A considerable proportion of patients with metabolic syndrome may be considered as having the signs of an early stage of heart failure of the HFpEF pattern. The use of objective parameters of exercise capacity and neurohormonal activation is justified for the early detection of heart failure with preserved ejection fraction. In the metabolic syndrome population initial stage of heart failure with preserved ejection fraction is associated with increased arterial stiffness.
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